Viridian Therapeutics, Inc.
VRDN
Positions held
Your positionsVRDN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Viridian Therapeutics is positioned in a growing biotechnology sector, focusing on innovative treatments that could address unmet medical needs.
- Revenue increased by 101% compared to the prior quarter, rising from $0.1M to $0.3M.
- The company's current ratio stands at an impressive 16.949, indicating strong liquidity.
- The company has a negative profit margin and is currently not generating profits, which raises concerns about its financial sustainability.
- Operating margin remains significantly negative at -44460.6%, reflecting ongoing operational challenges.
- The overall score indicates a 'Strong Sell' signal with a score of -24.00, highlighting bearish market sentiment.
Fundamentals
| Market cap | $2.08B | Enterprise value | $1.44B | Trailing P/E | — | Forward P/E | -6.69 |
| PEG | — | Price / book | 3.68 | Beta | 1.10 | Dividend yield | 0.00% |
| Revenue growth | 2.8% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -444.6% |
| Profit margin | 0.0% | ROE | -65.7% | ROA | -30.2% | Debt / equity | 0.37 |
| Current ratio | 16.95 | Free cash flow | -$275.50M | Analyst recommendation | strong_buy | Mean target | $36.75 |
| 52w high | $34.29 | 52w low | $13.18 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.3M | $0.1M | $0.1M | $70.6M | $0.1M | — |
| Op margin | -44460.6% | -82389.4% | -92991.7% | -56.7% | -142356.0% | — |
| Net income | -$127M | -$105M | -$120M | -$34.6M | -$101M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$126M | -$116M | -$123M | -$40.0M | -$107M | — |
- Revenue +101% vs prior quarter ($0.3M vs $0.1M).
- Operating margin expanded to -44460.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $70.8M | $0.3M | $0.3M | $1.8M | — |
| Op margin | -512.9% | -99018.2% | -81035.0% | -7579.2% | — |
| Net income | -$343M | -$270M | -$238M | -$130M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$363M | -$299M | -$254M | -$134M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-22 · Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says
2026-09-22 · RBC Raises Price Target on Viridian Therapeutics to $38 From $36, Keeps Outperform, Speculative Risk
2026-09-02 · Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
2026-08-07 · Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says
2026-08-07 · RBC Adjusts Viridian Therapeutics PT to $36 From $35, Maintains Outperform Speculative Risk Rating
2026-08-06 · Wedbush Adjusts PT on Viridian Therapeutics to $41 From $43, Maintains Outperform Rating
2026-08-06 · Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
2026-07-15 · Lumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN)
2026-07-15 · Viridian Therapeutics (VRDN) Rebounds Sharply, Is The Valuation Still Too Rich?
2026-07-15 · Viridian Therapeutics (VRDN) Stock Still Looks Above Fair Value Today
2026-07-14 · “Stay Invested”: Wells Fargo Picks 2 Stocks to Buy as It Stays Bullish on the Market
Price (daily)
Full chart · RSI · MACD · patterns